The 7 analysts offering 1 year price forecasts for 4IPH have a max estimate of — and a min estimate of —.
Analyst rating
Based on 7 analysts giving stock ratings to 4IPH in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
4IPH EPS for the last quarter is −0.31 EUR despite the estimation of −0.28 EUR. In the next quarter EPS is expected to reach −0.26 EUR. Track more of INNATE PHARMA financials and stay on top of what is up with the company.
In the next quarter INNATE PHARMA revenue is expected to reach 17.29 M EUR. Check out INNATE PHARMA revenue and earnings and make informed decisions.
According to analysts, 4IPH price target is 6.87 EUR with a max estimate of 11.50 EUR and a min estimate of 2.25 EUR. Check if this forecast comes true in a year, meanwhile watch INNATE PHARMA stock price chart and keep track of the current situation with 4IPH news and stock market news.
We've gathered opinions of 7 analysts rating 4IPH stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.